|Bid||3.0300 x 28000|
|Ask||3.0600 x 21500|
|Day's range||2.9800 - 3.1500|
|52-week range||2.5700 - 6.9500|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.59|
At this time, I would like to turn the call over to Shayne Laidlaw, investor relations. Today, I'm joined by our chairman, president, and CEO, Mike Gorenstein, and our CFO, Bob Madore. Before I turn the call over to Mike, let me remind you that we may make forward-looking statements and refer to non-GAAP financial measures during this call.
Shares of marijuana producer Cronos Group (NASDAQ: CRON) are plunging 13% as of 10:42 a.m. ET on Tuesday after it reported earnings that beat Wall Street projections on bottom-line losses but missed analyst revenue estimates. Cronos sells marijuana in Canada, Australia, Germany, and Israel but has focused particularly on the latter in more recent periods as it continues to see strong growth in the market. Revenue from Israel more than tripled over the past year, reaching $7.2 million, or 31% of Cronos' total revenue.
We see a preliminary non-farm -4.6% in Q2 Productivity, better than the -5% expected and the -7.3% from Q1, which was the worst productivity report since 1947.